Posters
Anemia: Global Burden, Disease Interactions, and Emerging Therapeutic Paradigms
October 23, 2026 | 10:00 AM - 12:00 PM
Location: Exhibit Hall A, Convention Center
Session Description
Poster Session
Posters
Global Burden of Anemia Due to CKD, 1990-2023, with Projections to 2045: A Benchmarking Analysis
Role of Osteoblast HNF4A2 in Anemia of CKD
An Engineered Tetravalent Antibody Is a More Effective and Sustained Erythropoiesis-Stimulating Agent Than Erythropoietin (EPO) in Models of EPO Deficiency and Anemia of CKD
A Novel Direct-to-Transferrin Iron Drug Ameliorates Anemia in a Rodent Model of CKD
Hepcidin and Mortality in Older Adults
CKD and Epistaxis with Reversal of Coagulopathy After Vitamin K Treatment
Effect of a Pharmacist-Led Erythropoietin-Stimulating Agent (ESA) Protocol on Patient Care in an Ambulatory Setting
Residual Kidney Function Is Associated with Hyporesponsiveness to Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Patients on Peritoneal Dialysis
Efficacy and Safety of Vadadustat vs. Erythropoiesis-Stimulating Agents for Anemia of CKD: An Updated Systematic Review and Meta-Analysis Including Novel Dosing Regimens
Cost Analysis of Hospitalizations for Vadadustat vs. Darbepoetin Alfa Based on the Phase 3 INNO2VATE Trials
Daily Dosing of Desidustat in Anemia of CKD: A Single-Centre Experience
Dual Erythropoiesis-Stimulating Agent and Desidustat Therapy for Management of Hyporesponsive Anemia of CKD: A Prospective Study
Efficacy and Safety of Enarodustat in Treating Anemia of Nondialysis-Dependent CKD: A National Multicenter Prospective Study (SET-ANEMIA STUDY)
Effects of Enarodustat vs. Roxadustat on Thyroid Function in Anemic Patients with CKD
Early Interim Analysis of Two Pegmolesatide Dosing Regimens in Anemia of Nondialysis-Dependent CKD: A Pooled Short-Term Experience
Hemoglobin Improvement After Pegmolesatide Initiation in Patients with Anemia of CKD on Dialysis: A 24-Week Interim Descriptive Analysis
Pegmolesatide Mitigates CKD-Associated Anemia by Targeting Liver Sinusoidal Endothelial Cells to Inhibit the BMP6-Smad-Hepcidin Axis
Association Between Serum 1,25-Dihydroxyvitamin D Levels and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Patients with Predialysis CKD
Associations of Extended-Hours Hemodialysis with Iron Metabolism and Erythropoietin Resistance: The LIBERTY Cohort
Inflammatory and Nutritional Biomarkers Associated with Erythropoiesis-Stimulating Agent Hyporesponsiveness in Patients on Hemodialysis: Prognostic Value of Lymphocyte-to-Albumin Ratio and Haptoglobin
Elevated Serum Ferritin Levels and Infection-Related Mortality in Patients on Maintenance Hemodialysis: Ten-Year Outcomes of the Q-Cohort Study
Myeloid Ferritin Heavy Chain Limits Systemic Iron Mobilization and Drives Anemia of CKD
Changes in Total Body Iron and the Effect of Low-Dose Oral Iron in Patients on Hemodialysis
Short-Term Infectious Outcomes After Intravenous vs. Oral Iron Therapy: A Target Trial Emulation Study
Muscle Strengthening Is Associated with Reduced Serum Soluble Fas Levels and Erythropoiesis-Stimulating Agent Requirement in Patients Receiving Hemodiafiltration
Rule-Based Algorithms for Anemia Management and Patient Outcomes in Patients on Maintenance Hemodialysis
Association Between SGLT2 Inhibitors and New-Onset Anemia of CKD
Hemoglobin and CKD in Patients with Diabetes
Diabetes Attenuates Iron Therapy Response in CKD: Unveiling the Role of Functional Iron Deficiency
Bilateral Spontaneous Renal Hemorrhage Presenting as Acute Anemia in Pyelonephritis and Newly Diagnosed Diabetes
Kidney Function-Adjusted Hemoglobin Thresholds as a Clue to Multiple Myeloma in CKD